Suspected product tampering has put production at a French Catalent plant on hold--and GlaxoSmithKline is paying the price. The British pharma giant has delayed the launch of hair-loss drug Zagallo in Japan while it searches for another manufacturing site.
Catalent's production interruption at a French plant because of suspected product tampering is being felt by clients. GlaxoSmithKline has had to delay the launch of a hair loss drug in Japan while it figures out another location that can produce it.
Vancouver-based Zymeworks has added another marquee collaboration to its growing list of development partnerships.
Research published by the Journal of Adolescent Health demonstrates a reality that Big Pharmas Merck and GlaxoSmithKline have experienced for years: there's an abundance of misinformation regarding HPV vaccines.
The more researchers know about patient adherence to drugs, the better they can adapt products to keep patients compliant--which, in turn, helps pad sales. Makers of respiratory drugs have picked up on that lately, and now, GlaxoSmithKline is the latest to forge an adherence-minded technology deal.
A new study published in the Journal of Adolescent Health found that parents looking online for information about HPV vaccines can be misled by websites containing inaccurate or incomplete medical information, Reuters reported.
Fierce 15 company Propeller Health has announced an R&D collaboration with GlaxoSmithKline, under which it will design and manufacture a custom sensor for the Ellipta inhaler to be used in GSK clinical studies of asthma and COPD.
Since Chinese officials slapped GlaxoSmithKline with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption there. But some in the industry say its reforms--which include eliminating sales-based compensation incentives for reps, nixing doctor speaking fees and tripling an in-house compliance team that checks every submitted receipt--could be negatively impacting its top line at a time when the company's already hurting.
Since Chinese officials slapped GlaxoSmithKline with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption. But some say its reforms could hurt its top line at a time when the company's already suffering.
A new study shows that prices for 19 brand-name dermatology meds, including two from Valeant Pharmaceuticals, have increased almost fivefold, on average, over the past 6 years.